摘要
目的考察复方益肝灵系列品种体外生物利用度一致性。方法建立复方益肝灵系列品种体外溶出度的评价方法,通过考察复方益肝灵不同剂型、不同生产企业的体外溶出曲线,对其生物利用度进行评价。结果多数生产企业的批内溶出量RSD>10%,批间及不同企业样品的溶出曲线差异较大,水飞蓟素累积溶出度普遍低于75%,与进口同类制剂的生物利用度比较有一定的差异。结论应加强中药制剂的生物利用度合理研究,以保证临床合理用药。
Objective To investigate the in-vitro bioavailability Methods The in-vitro bioavailability of compound Yiganling dissolution determination method and by studying the dissolution consistency of compound Yiganling series varieties. series varieties was evaluated by developing the curves of compound Yiganling in different forms and from different enterprises. Results The intra-batch RSDs of dissolution rate of compound Yiganling from most of the enterprises were more than 10 %, and there was a great difference in the inter-batch and inter-enterprise dissolution curves. Meanwhile, the accumulated dissolution rate of silymarin was generally lower than 75 %, which was lower than that of the imported counterparts. Conclusion Research of the bioavailability of traditional Chinese medicine preparations should be strengthened.
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2015年第5期682-685,共4页
Traditional Chinese Drug Research and Clinical Pharmacology
